197 related articles for article (PubMed ID: 36461910)
21. Analysis of Tumor Angiogenesis and Immune Microenvironment in Non-Functional Pituitary Endocrine Tumors.
Sato M; Tamura R; Tamura H; Mase T; Kosugi K; Morimoto Y; Yoshida K; Toda M
J Clin Med; 2019 May; 8(5):. PubMed ID: 31100921
[TBL] [Abstract][Full Text] [Related]
22. Combined GM-CSF treatment and M-CSF inhibition of tumor-associated macrophages induces dendritic cell-like signaling in vitro.
Kitoh Y; Saio M; Gotoh N; Umemura N; Nonaka K; Bai J; Vizkeleti L; Torocsik D; Balazs M; Adany R; Takami T
Int J Oncol; 2011 May; 38(5):1409-19. PubMed ID: 21373754
[TBL] [Abstract][Full Text] [Related]
23. Progress in the Pathogenesis, Diagnosis, and Treatment of TSH-Secreting Pituitary Neuroendocrine Tumor.
Luo P; Zhang L; Yang L; An Z; Tan H
Front Endocrinol (Lausanne); 2020; 11():580264. PubMed ID: 33329389
[TBL] [Abstract][Full Text] [Related]
24. Macrophage colony-stimulating factor induces prolactin expression in rat pituitary gland.
Hoshino S; Kurotani R; Miyano Y; Sakahara S; Koike K; Maruyama M; Ishikawa F; Sakatai I; Abe H; Sakai T
Zoolog Sci; 2014 Jun; 31(6):390-7. PubMed ID: 24882100
[TBL] [Abstract][Full Text] [Related]
25. Pituitary tumour fibroblast-derived cytokines influence tumour aggressiveness.
Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Awad S; Dorward N; Grieve J; Mendoza N; Muquit S; Grossman AB; Balkwill F; Korbonits M
Endocr Relat Cancer; 2019 Dec; 26(12):853-865. PubMed ID: 31645017
[TBL] [Abstract][Full Text] [Related]
26. A unique anti-CD115 monoclonal antibody which inhibits osteolysis and skews human monocyte differentiation from M2-polarized macrophages toward dendritic cells.
Haegel H; Thioudellet C; Hallet R; Geist M; Menguy T; Le Pogam F; Marchand JB; Toh ML; Duong V; Calcei A; Settelen N; Preville X; Hennequi M; Grellier B; Ancian P; Rissanen J; Clayette P; Guillen C; Rooke R; Bonnefoy JY
MAbs; 2013; 5(5):736-47. PubMed ID: 23924795
[TBL] [Abstract][Full Text] [Related]
27. DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Tumoral Pituitary Cells.
Mangili F; Esposito E; Treppiedi D; Catalano R; Marra G; Di Muro G; Barbieri AM; Locatelli M; Lania AG; Mangone A; Spada A; Arosio M; Peverelli E; Mantovani G
Front Endocrinol (Lausanne); 2022; 13():867822. PubMed ID: 35721701
[TBL] [Abstract][Full Text] [Related]
28. Annotation of pituitary neuroendocrine tumors with genome-wide expression analysis.
Tebani A; Jotanovic J; Hekmati N; Sivertsson Å; Gudjonsson O; Edén Engström B; Wikström J; Uhlèn M; Casar-Borota O; Pontén F
Acta Neuropathol Commun; 2021 Nov; 9(1):181. PubMed ID: 34758873
[TBL] [Abstract][Full Text] [Related]
29. Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages.
Mete O; Alshaikh OM; Cintosun A; Ezzat S; Asa SL
Endocr Pathol; 2018 Dec; 29(4):332-338. PubMed ID: 30215160
[TBL] [Abstract][Full Text] [Related]
30. Receptor for macrophage colony-stimulating factor transduces a signal decreasing erythroid potential in the multipotent hematopoietic EML cell line.
Pawlak G; Grasset MF; Arnaud S; Blanchet JP; Mouchiroud G
Exp Hematol; 2000 Oct; 28(10):1164-73. PubMed ID: 11027835
[TBL] [Abstract][Full Text] [Related]
31. [WHO Histological Classification of Pituitary Tumors].
Nishioka H
No Shinkei Geka; 2023 Jul; 51(4):642-653. PubMed ID: 37491061
[TBL] [Abstract][Full Text] [Related]
32. Clinical presentation and recurrence of pituitary neuroendocrine tumors: results from a single referral center in Colombia.
Jimenez-Canizales CE; Rojas W; Alonso D; Romero I; Tabares S; Veronesi Zuluaga LA; Modica R; Colao A
J Endocrinol Invest; 2023 Nov; 46(11):2275-2286. PubMed ID: 37002436
[TBL] [Abstract][Full Text] [Related]
33. IL-34 and M-CSF form a novel heteromeric cytokine and regulate the M-CSF receptor activation and localization.
Ségaliny AI; Brion R; Brulin B; Maillasson M; Charrier C; Téletchéa S; Heymann D
Cytokine; 2015 Dec; 76(2):170-181. PubMed ID: 26095744
[TBL] [Abstract][Full Text] [Related]
34. Colony-Stimulating Factor 1 Receptor Blockade Inhibits Tumor Growth by Altering the Polarization of Tumor-Associated Macrophages in Hepatocellular Carcinoma.
Ao JY; Zhu XD; Chai ZT; Cai H; Zhang YY; Zhang KZ; Kong LQ; Zhang N; Ye BG; Ma DN; Sun HC
Mol Cancer Ther; 2017 Aug; 16(8):1544-1554. PubMed ID: 28572167
[TBL] [Abstract][Full Text] [Related]
35. Multiple tumorous lesions of the pituitary gland.
Schöning JV; Flitsch J; Lüdecke DK; Fahlbusch R; Buchfelder M; Buslei R; Knappe UJ; Bergmann M; Schulz-Schaeffer WJ; Herms J; Glatzel M; Saeger W
Hormones (Athens); 2022 Dec; 21(4):653-663. PubMed ID: 35947342
[TBL] [Abstract][Full Text] [Related]
36. Co-occurrence of Pituitary Neuroendocrine Tumors (PitNETs) and Tumors of the Neurohypophysis.
Saeger W; von Schöning J; Flitsch J; Jautzke G; Bergmann M; Hagel C; Knappe UJ
Endocr Pathol; 2021 Dec; 32(4):473-479. PubMed ID: 34129177
[TBL] [Abstract][Full Text] [Related]
37. Detection of tumor-specific DNA methylation markers in the blood of patients with pituitary neuroendocrine tumors.
Herrgott GA; Asmaro KP; Wells M; Sabedot TS; Malta TM; Mosella MS; Nelson K; Scarpace L; Barnholtz-Sloan JS; Sloan AE; Selman WR; deCarvalho AC; Poisson LM; Mukherjee A; Robin AM; Lee IY; Snyder J; Walbert T; Rosenblum M; Mikkelsen T; Bhan A; Craig J; Kalkanis S; Rock J; Noushmehr H; Castro AV
Neuro Oncol; 2022 Jul; 24(7):1126-1139. PubMed ID: 35212383
[TBL] [Abstract][Full Text] [Related]
38. Beyond the M-CSF receptor - novel therapeutic targets in tumor-associated macrophages.
Bonelli S; Geeraerts X; Bolli E; Keirsse J; Kiss M; Pombo Antunes AR; Van Damme H; De Vlaminck K; Movahedi K; Laoui D; Raes G; Van Ginderachter JA
FEBS J; 2018 Feb; 285(4):777-787. PubMed ID: 28834216
[TBL] [Abstract][Full Text] [Related]
39. Quantitative Acetylomics Revealed Acetylation-Mediated Molecular Pathway Network Changes in Human Nonfunctional Pituitary Neuroendocrine Tumors.
Wen S; Li J; Yang J; Li B; Li N; Zhan X
Front Endocrinol (Lausanne); 2021; 12():753606. PubMed ID: 34712204
[TBL] [Abstract][Full Text] [Related]
40. PD-L1 Is Preferentially Expressed in PIT-1 Positive Pituitary Neuroendocrine Tumours.
Turchini J; Sioson L; Clarkson A; Sheen A; Gill AJ
Endocr Pathol; 2021 Sep; 32(3):408-414. PubMed ID: 33694064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
